Stocks and Investing Stocks and Investing
Thu, November 28, 2024
[ 11:21 AM ] - United States, Thomas Matters
Low costs, potential gains increasingly drawing investors to active ETFs
[ 11:21 AM ] - United States, Thomas Matters
Palantir Vs. Super Micro Computer: A Tale Of Two Camps
[ 11:21 AM ] - United States, Thomas Matters
Invest Smart: The Best Funds to Grow Your Money Today
[ 11:21 AM ] - United States, Thomas Matters
Investing in the Stock Market with Just ?10: Is It Possible?
[ 11:21 AM ] - United States, Thomas Matters
The top ten stocks investors hold in their Isas - .. how much tax-free investing could have saved them
[ 11:21 AM ] - United States, Thomas Matters
SPGP: Balancing Growth And Value, But Falling Short
[ 09:21 AM ] - United States, Thomas Matters
Money blog: Anger as Manchester United raise ticket prices to cover operational costs
[ 09:21 AM ] - United States, Thomas Matters
Stocks slip the day before Thanksgiving as Nvidia, Dell decline
[ 09:21 AM ] - United States, Thomas Matters
These are the top 3 risks to the US stock market rally, according to Deutsche Bank
[ 09:20 AM ] - United States, Thomas Matters
The5%ers Review 2024: Everything You Need to Know Before Signing Up
[ 09:01 AM ] - United States, Thomas Matters
Is Pfizer Stock in Trouble?
[ 09:00 AM ] - United States, Thomas Matters
Building Long-Term Wealth: Why I Chose This Vanguard Growth Fund for My Roth IRA
[ 08:40 AM ] - United States, Thomas Matters
Stock market today: World shares are mostly higher after Big Tech losses pull Wall St lower
[ 07:41 AM ] - United States, Thomas Matters
MoneyLion: 3 Key Reasons This Under-The-Radar Growth Story Is A 'Strong Buy'
[ 07:40 AM ] - United States, Thomas Matters
4 Stocks to Be Thankful for, and 1 to Avoid
[ 06:21 AM ] - United States, Thomas Matters
How To Calculate Your Portfolio's Investment Returns
[ 06:21 AM ] - United States, Thomas Matters
36% of Nvidia's $35 Billion in Q3 Revenue Came From Just 3 Mystery Customers
[ 06:21 AM ] - United States, Thomas Matters
Is now a good time to invest in silver?
[ 06:20 AM ] - United States, Thomas Matters
Here Are Billionaire Bill Ackman's 5 Biggest Stock Holdings
[ 05:40 AM ] - United States, Thomas Matters
President-Elect Donald Trump Is About to Make Dubious Stock Market History
[ 05:20 AM ] - United States, Thomas Matters
DRA Homes signs up Rashmika Mandanna as brand ambassador
[ 05:20 AM ] - United States, Thomas Matters
Sweden's Nalka Is Said to Pick Banks for Healthcare Unit IPO
[ 04:40 AM ] - United States, Thomas Matters
The best Vanguard ASX ETF to invest $2,000 in right now
[ 04:21 AM ] - United States, Thomas Matters
Stock market today: Wall Street wavers as Big Tech stocks fall
[ 04:21 AM ] - United States, Thomas Matters
Wall Street sees 'no alternative' to U.S. stocks in 2025. Here's why.
[ 04:20 AM ] - United States, Thomas Matters
Here's the Average Stock Market Return Over the L .. 10 Years, and What It Means for the Next 10 Years
[ 03:20 AM ] - United States, Thomas Matters
Why Is Structure Therapeutics Inc. (GPCR) Among t .. p and Coming Stocks to Buy According to Analysts?
[ 03:01 AM ] - United States, Thomas Matters
Stock market today: Losses for Big Tech pull US indexes lower
[ 03:00 AM ] - United States, Thomas Matters
What Happens To Your Money When A Mutual Fund Scheme Is Closed?
[ 02:40 AM ] - United States, Thomas Matters
Embecta upgraded to Buy from Neutral at BTIG

Embecta upgraded to Buy from Neutral at BTIG


Published on 2024-11-28 02:40:57 - Thomas Matters, WOPRAI
  Print publication without navigation

  • BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded

Embecta, a medical device company focused on diabetes care, was upgraded to a "Buy" rating from "Neutral" by BTIG analyst Marie Thibault. This upgrade was based on the company's strong performance in its core business, particularly in the U.S. where it holds a significant market share in insulin syringes and pen needles. The analyst highlighted that despite potential challenges like the loss of exclusivity for some products, Embecta's strategic initiatives, including new product launches and international expansion, are expected to drive growth. Additionally, the company's efforts to manage costs and improve operational efficiency were noted as positive factors contributing to the optimistic outlook. The price target set by BTIG for Embecta's stock reflects confidence in its future profitability and market position.

Read the Full Business Insider Article at [ https://markets.businessinsider.com/news/stocks/embecta-upgraded-to-buy-from-neutral-at-btig-1034071393 ]

Contributing Sources